DiaMedica Therapeutics (DMAC) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed Editas Medicine (EDIT) over the past year, gaining 16.5% versus a loss of 30.0%. Over five years, DMAC leads with a +94.9% price change compared with -92.8% for EDIT. DiaMedica Therapeutics is the larger company by market cap ($430.9 million vs $422.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | EDIT |
|---|---|---|
| Share price | $7.99 | $2.75 |
| Market cap | $430.87M | $422.35M |
| 1-day change | -1.72% | +0.73% |
| YTD return | +0.38% | +34.15% |
| 1-year return | +16.47% | -30.03% |
| 5-year return | +94.88% | -92.77% |
| EPS (TTM) | $-0.72 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.42 | $4.33 |
| 52-week low | $5.25 | $1.66 |
| Distance from 52-week high | -23.32% | -36.49% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +93.99% | +114.55% |
| Average volume | 175.72K | 2.48M |
| Shares outstanding | 53.93M | 153.58M |
| Employees | 35 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed EDIT by 46.5 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
DMAC vs EDIT FAQ
Which is bigger, DiaMedica Therapeutics or Editas Medicine?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $430.87M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, DMAC or EDIT?
DMAC returned +16.47% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Editas Medicine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for DiaMedica Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Editas Medicine.